Cargando...
4CPS-107 An estimate of avoided costs for drugs in patients included in non-small lung cancer clinical trials
BACKGROUND: The economic impact of non-small cell lung cancer (NSCLC) is increasing. Clinical trials (CT) are essential for evaluating the efficacy and safety of new treatments, but they can also have an economic benefit by avoiding drug costs. PURPOSE: Our aim was to determine the avoided cost attr...
Guardado en:
| Publicado en: | Eur J Hosp Pharm |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BMJ Group
2018
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535720/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.198 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|